MAFLD: Renovation of clinical practice and disease awareness of fatty liver

Kawaguchi, Takumi; Tsutsumi, Tsubasa; Nakano, Dan; Torimura, Takuji

doi:10.1111/hepr.13706

Cited by 73 publications

(96 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another important distinction is that MAFLD is independent of alcoholic intake or other liver diseases, including viral hepatitis. Therefore, patients with dual (or more) etiologies of liver disease can be diagnosed with “MAFLD and alcoholic liver disease” or “MAFLD and chronic hepatitis B (CH-B).” [ 49 , 50 ] Therefore, MAFLD allows us to investigate the impact of coexisting fatty liver in patients with viral hepatitis. Such assessments will also impact studies of viral hepatitis and MAFLD in their contribution to HCC development.…”

Section: Metabolic Dysfunction-associated Fatty Liver Disease (Mafld)mentioning

confidence: 99%

MAFLD enhances clinical practice for liver disease in the Asia-Pacific region

et al. 2022

Self Cite

View full text Add to dashboard Cite

Fatty liver is now a major cause of liver disease in the Asia-Pacific region. Liver diseases in this region have distinctive characteristics. First, fatty liver is frequently observed in lean/normal-weight individuals. However, there is no standard definition of this unique phenotype. Second, fatty liver is often observed in patients with concomitant viral hepatitis. The exclusion of viral hepatitis from non-alcoholic fatty liver disease limits its value and detracts from the investigation and holistic management of coexisting fatty liver in patients with viral hepatitis. Third, fatty liver-associated hepatocellular carcinoma (HCC) is generally categorized as non-B non-C HCC. Fourth, the population is aging rapidly, and it is imperative to develop a practicable, low-intensity exercise program for elderly patients. Fifth, most patients and nonspecialized healthcare professionals still lack an awareness of the significance of fatty liver both in terms of intrahepatic and extrahepatic disease and cancer. Recently, an international expert panel proposed a new definition of fatty liver: metabolic dysfunction-associated fatty liver disease (MAFLD). One feature of MAFLD is that metabolic dysfunction is a prerequisite for diagnosis. Pertinent to regional issues, MAFLD also provides its diagnostic criteria in lean/normal-weight individuals. Furthermore, MAFLD is independent of any concomitant liver disease, including viral hepatitis. Therefore, MAFLD may be a more suitable definition for fatty liver in the Asia-Pacific region. In this review, we introduce the regional characteristics of fatty liver and discuss the advantages of MAFLD for improving clinical practice for liver disease in the region.

show abstract

Section: Metabolic Dysfunction-associated Fatty Liver Disease (Mafld)mentioning

confidence: 99%

MAFLD enhances clinical practice for liver disease in the Asia-Pacific region

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…The negative effect of metabolic syndrome and insulin resistance on liver disease has been widely explained, and it is represented by a spectrum of conditions ranging from liver steatosis to NASH, and, in a later stage, liver fibrosis and cirrhosis [47][48][49]. No data are available on the risk of liver disease in CCS.…”

Section: Discussionmentioning

confidence: 99%

Influence of Body Mass Index, Cancer Type and Treatment on Long-Term Metabolic and Liver Outcomes in Childhood Cancer Survivors

Milluzzo

Manuella

Cannata

et al. 2022

JCM

View full text Add to dashboard Cite

In the last decade, the survival of subjects affected by cancer in childhood has significantly improved. The increased lifespan of childhood cancer survivors (CCS) led to a greater risk for long-term, therapy-related morbidity. To identify the clinical predictors of metabolic adverse outcomes in CCS (average off-therapy period: 12 years), we recruited 126 survivors of different childhood cancers (86.5% hematological cancers) who received at least anticancer chemotherapy, consecutively approached during their annual oncohematological outpatient visit. At examination, anthropometric measures and cancer-related history were collected. Moreover, a fasting venous sample was carried out for measuring fasting plasma glucose and insulin, glycated hemoglobin, lipid panel, and transaminases. We calculated the indexes of insulin resistance (HOMA-IR, McAuley, and QUICKI) and secretion (HOMA-β), liver steatosis (Hepatic Steatosis Index) and fibrosis (FIB-4 and NAFLD fibrosis score), and visceral fat dysfunction (Visceral Adiposity Index). More than one-third of the subjects (37.3%) did not have normal weight, with 11.1% of them affected by obesity. At recruitment, obese subjects were at significantly higher risk for impaired fasting glucose, metabolic syndrome, visceral adipose dysfunction, and liver steatosis/fibrosis. Subjects who received bone marrow transplantation were prone to insulin resistance, while survivors of lymphoma presented a visceral adipose dysfunction These results suggest a carefully metabolic monitoring of CCS, particularly in subgroups at higher risk, to early detect these conditions, promptly begin therapeutic interventions, and mitigate the dysmetabolic-related health burden.

show abstract

“…[10] This failure is likely explained at least partially by the underlying heterogeneity of MAFLD and their main disease drivers that failed to be captured under the NAFLD definition, making a one-sizefits-all approach unlikely. [11][12][13][14] The details of the pipeline of the investigational candidate drugs for MAFLD and potential reasons for the suboptimal performance of these drugs in clinical trials have been the subject of multiple recent reviews. [5,[15][16][17] Transformational changes and novel targets and concepts are needed to address MAFLD-related morbidity and mortality.…”

Section: Translation Reprogramming As a Novel Therapeutic Target In M...mentioning

confidence: 99%

Translation Reprogramming as a Novel Therapeutic Target in MAFLD

et al. 2022

View full text Add to dashboard Cite

Approved pharmacotherapies for metabolic‐dysfunction‐associated fatty liver disease (MAFLD) are lacking. Novel approaches and therapeutic targets that are likely to translate to clinical benefit are required. Targeting components of the translation machinery hold promise as a novel therapeutic approach that can overcome the well‐known disease heterogeneity, as dysregulation of mRNA translation is a common feature independent of the MAFLD drivers. In this perspective, recent advances in understanding the role of mRNA translation in MAFLD are discussed, with a particular focus on the potential implications and challenges to “translate” these findings to the clinic, and an overview of similar recent efforts in other diseases is provided.

show abstract

MAFLD: Renovation of clinical practice and disease awareness of fatty liver

Cited by 73 publications

References 97 publications

MAFLD enhances clinical practice for liver disease in the Asia-Pacific region

MAFLD enhances clinical practice for liver disease in the Asia-Pacific region

Influence of Body Mass Index, Cancer Type and Treatment on Long-Term Metabolic and Liver Outcomes in Childhood Cancer Survivors

Translation Reprogramming as a Novel Therapeutic Target in MAFLD

Contact Info

Product

Resources

About